The 340B program was initiated in 1992 by the US Congress to allow participating hospitals to generate additional revenue by purchasing certain drugs used for outpatient care at an approximately 22% discount while charging payers the full price. 1, 2 The program was designed to support hospitals caring for uninsured patients and low-income patients with Medicare and Medicaid coverage, allowing the hospitals to reach "more eligible patients" and provide "more comprehensive services." 2(p3) Although the 340B program was initially targeted to a select group of hospitals, participation has swelled, owing to expanded eligibility in 2004 and 2010 and the program's popularity. 1 Effective January 2018, the Centers for Medicare & Medicaid Services reduced Medicare reimbursement to physicians administering discounted drugs acquired by most 340B hospital participants. 3 Opponents of reform contend that 340B revenues finance safety-net services, 4 whereas supporters contend that most participants do not direct revenue back to safety-net care. 5 We examined how uncompensated care, provision of low-profit services, and financial stability differed between nonprofit and public hospital 340B participants and nonparticipants in 2015.
Methods | We linked data from 1224 general acute care nonprofit and public hospitals from the Healthcare Cost Report Information System to 660 hospitals participating in the 340B program from the Health Resource & Services Administration's provider list in 2015. Our sample was limited to urban hospitals with 100 or more beds that were not affected by eligibility expansions. The sample included nonprofit and public general acute-care hospitals that were not the target of direct eligibility expansions of 340B in 2010 or of indirect eligibility expansions of 340B eligibility through changes to the disproportionate-share hospital percentage adjustment in 2004. The sample excluded 115 hospitals that began participating in the program before 2015 but were no longer participating in 2015, 44 hospitals with missing data on the outcomes, and 21 observations representing more or less than 1 year. Owing to the use of publicly available data, the institutional review board of Vanderbilt University determined that the study was exempt from the need for review. We compared 340B hospital participants with those that never participated with respect to their patient populations and US Census Bureau-reported community characteristics. We further divided participants into cohorts based on the date when they first registered for the program. We examined differences in uncompensated care, provision of low-profit services, and financial services from the hospitals' cost reports using multivariable ordinary least-squares regressions with
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Letters controls adjusting for differences in hospital and community characteristics. Stata, version 14.1 (StataCorp Inc) was used for the statistical analysis; differences are considered significant at P < .05. In a comparison of all hospitals participating in the 340B program with nonparticipants in 2015, participants were less financial stable (−2.11% vs −1.74%; mean percentage point [PP] difference, 2.34%; 95% CI, −3.44% to −1.24%) and had slightly higher uncompensated care burden (4.10% vs 3.13%; mean adjusted PP difference, 0.08%; 95% CI, 0.38% to 1.26%) but were no more likely to offer low-profit services (48.18% vs 36.88%; mean adjusted PP difference, 5.33%; 95% CI, −0.54% to 11.21%) (Table) .
When we compared early participants with nonparticipants, the former spent more of their budget on uncompensated care (5.94% vs 3.13%; adjusted mean PP difference, 2.04%; 95% CI, 1.21% to 2.87%) and were more likely to offer low-profit services (62.89% vs 36.88%; adjusted mean PP difference, 8.79%; 95% CI, 0.17% to 17.41%) despite operating at a relative loss (−6.65% vs 2.11%; mean adjusted PP differ- CI, −7.62% to 11.96%) participants were more likely to offer lowprofit services.
Discussion | As of 2015, 41.8% of all nonprofit and public general acute-care hospitals participated in the 340B program. Although participating hospitals provided more uncompensated care and low-profit services to patients despite worse finances than nonparticipants, later participants-most hospitals-spent less of their budget on uncompensated care and were more financially stable compared with earlier participants. Our results should be interpreted as descriptive owing to unmeasured confounding, and some of our outcome measures may be reported with error. 6 Recent reimbursement reforms will likely have different effects across 340B participants. Targeting cuts might mitigate potential adverse effects on participants that provide a large amount of charitable medical care and operate at a substantial loss. 
Reforming the 340B Drug Pricing Program: Tradeoffs Between Hospital and Manufacturer Revenues
The maligned and ardently defended 340B drug pricing program allows qualifying hospitals and clinics (those serving a disproportionate share of low-income patients or receiving federal grants to provide specific services) to generate revenue by purchasing prescription drugs from pharmaceutical manufacturers at discounted prices while being reimbursed by Medicare and other payers at standard levels. 1 The discounted price available to 340B purchasers has 2 components: a fixed base discount (23.1% for brand drugs) and an additional discount triggered by manufacturer price increases greater than inflation (termed the inflation penalty). This inflation penalty accounts for more than one-half of the 340B discount. -and their affiliated locations have become eligible for the 340B program with Medicaid expansion 1 and health care sector consolidation, particularly in oncology. 5 Hospitals and clinics have also become more adept at capturing eligible drug purchases through expanded 340B pharmacy networks. As the population ages, more care is delivered through hospital outpatient departments, and more physician-administered drugs are used, further increasing the program's size. In 2015, 340B discounts were $6 billion on $12 billion in sales, 6 equating to a net reduction in total manufac- substantially differ in kind from non-340B hospitals by providing more uncompensated care and operating at lower margins; some 340B hospitals also provide more low-profit services. Of note, because 340B-purchased drugs can only be used in outpatient settings, inpatient low-profit service lines do not benefit directly from 340B purchasing, but they may benefit indirectly. Policy proposals requiring that 340B savings be allocated directly to outpatients or outpatient services could decrease the ability of 340B hospitals to fund low-profit inpatient services. Because late 340B entrants became eligible when their patients gained Medicaid coverage, this cohort might be expected to have lower levels of uncompensated care and higher operating margins than early entrants to the 340B program; they still, however, provide more uncompensated care and have lower operating margins than non-340B hospitals. The study by Nikpay et al 7 did not evaluate other potential uses of 340B revenue, such as community benefit spending, which may be important considerations for 340B reform. Recent administrative and proposed legislative policy changes have the potential to markedly alter the 340B program. On January 1, 2018, 340B hospitals received a 27% cut in Medicare Part B reimbursement for drugs purchased at the 340B price. 4 This cut will reduce 340B revenue to qualifying hospitals, and Medicare will reallocate the funds to other entities, maintaining overall budget neutrality. In responding to this change, some 340B hospitals may elect to maximize their revenue by opting out of the program for certain drugs, thereby purchasing drugs at full price and receiving more lucrative standard Medicare reimbursement. 4 The net effect would be to transfer Medicare spending from the 340B hospital to the pharmaceutical manufacturer. Similarly, any narrowing of 340B eligibility to a smaller set of qualifying institutions would transfer the corresponding share of government payment for drugs from the hospital or the clinic to the manufacturer. Nikpay et al 7 support an informed debate by demonstrating that 340B hospitals provide greater levels of uncompensated care and have lower operating margins than non-340B
Related article page 1124 hospitals; these financial differences would likely be exacerbated with any reduction in 340B revenue. However, the public and policy makers would be well served by greater transparency on hospitals' use of 340B revenues, as suggested by lawmakers. Because any reduction in 340B eligibility increases manufacturer revenues, increased transparency will help policy makers characterize the benefits to patients when considering tradeoffs between hospital and manufacturer revenues from any changes to the program.
